Gisslen M - Search Results

1

Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy.

Anderson AM, Kundu S, Tang B, Vaida F, Okwuegbuna O, McClernon D, Cherner M, Deutsch R, Cookson D, Crescini M, Grant I, Zetterberg H, Blennow K, Gisslen M, Ellis RJ, Letendre SL. Anderson AM, et al. Among authors: gisslen m. J Neuroimmunol. 2021 Apr 15;353:577493. doi: 10.1016/j.jneuroim.2021.577493. Epub 2021 Jan 21. J Neuroimmunol. 2021. PMID: 33571816 Free PMC article.

2

Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection.

Abdulle S, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Abdulle S, et al. Among authors: gisslen m. AIDS. 2002 Nov 8;16(16):2145-9. doi: 10.1097/00002030-200211080-00006. AIDS. 2002. PMID: 12409735

3

Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.

Yilmaz A, Ståhle L, Hagberg L, Svennerholm B, Fuchs D, Gisslén M. Yilmaz A, et al. Among authors: gisslen m. Scand J Infect Dis. 2004;36(11-12):823-8. doi: 10.1080/00365540410025320. Scand J Infect Dis. 2004. PMID: 15764168 Clinical Trial.

4

Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection.

Cinque P, Bestetti A, Marenzi R, Sala S, Gisslen M, Hagberg L, Price RW. Cinque P, et al. Among authors: gisslen m. J Neuroimmunol. 2005 Nov;168(1-2):154-63. doi: 10.1016/j.jneuroim.2005.07.002. Epub 2005 Aug 8. J Neuroimmunol. 2005. PMID: 16091292

5

Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.

Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, Gisslén M. Mellgren A, et al. Among authors: gisslen m. Antivir Ther. 2005;10(6):701-7. Antivir Ther. 2005. PMID: 16218168 Clinical Trial.

6

Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia--case report.

Andersson LM, Hagberg L, Rosengren L, Fuchs D, Blennow K, Gisslén M. Andersson LM, et al. Among authors: gisslen m. BMC Infect Dis. 2006 Sep 15;6:141. doi: 10.1186/1471-2334-6-141. BMC Infect Dis. 2006. PMID: 16978408 Free PMC article.

7

Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.

Yilmaz A, Svennerholm B, Hagberg L, Gisslén M. Yilmaz A, et al. Among authors: gisslen m. Antivir Ther. 2006;11(7):833-7. Antivir Ther. 2006. PMID: 17302245

8

Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers.

Gisslen M, Hagberg L, Rosengren L, Brew BJ, Cinque P, Spudich S, Price RW. Gisslen M, et al. J Neuroimmune Pharmacol. 2007 Mar;2(1):112-9. doi: 10.1007/s11481-006-9035-1. Epub 2006 Sep 12. J Neuroimmune Pharmacol. 2007. PMID: 18040834 Review.

9

Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.

Edén A, Price RW, Spudich S, Fuchs D, Hagberg L, Gisslén M. Edén A, et al. Among authors: gisslen m. J Infect Dis. 2007 Dec 15;196(12):1779-83. doi: 10.1086/523648. J Infect Dis. 2007. PMID: 18190258

10

Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals.

Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, Timmerman P, Gisslén M. Yilmaz A, et al. Among authors: gisslen m. AIDS Res Hum Retroviruses. 2009 Apr;25(4):457-61. doi: 10.1089/aid.2008.0216. AIDS Res Hum Retroviruses. 2009. PMID: 19320601 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

311 results

Search Page

Filters